Exelixis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$EXEL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 28, 2025
 | ||
| (Exact name of registrant as specified in its charter) | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(650 ) 837-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
(a) On May 28, 2025, Exelixis held its Annual Meeting via live webcast.
(b) The results of the matters submitted to a stockholder vote at the Annual Meeting were as follows:
1.Election of Directors: Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2026, and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | ||||||||||||||||||||
Mary C. Beckerle, Ph.D. | 221,778,432 | 3,975,476 | 244,544 | 23,953,528 | |||||||||||||||||||
S. Gail Eckhardt, M.D. | 224,128,884 | 1,690,828 | 178,740 | 23,953,528 | |||||||||||||||||||
Maria C. Freire, Ph.D. | 221,355,137 | 4,460,355 | 182,960 | 23,953,528 | |||||||||||||||||||
Tomas J. Heyman | 217,960,865 | 7,857,654 | 179,933 | 23,953,528 | |||||||||||||||||||
David E. Johnson | 224,162,314 | 1,646,113 | 190,025 | 23,953,528 | |||||||||||||||||||
Michael M. Morrissey, Ph.D. | 223,617,463 | 2,200,222 | 180,767 | 23,953,528 | |||||||||||||||||||
Robert L. Oliver, Jr. | 223,657,357 | 2,160,684 | 180,411 | 23,953,528 | |||||||||||||||||||
Stelios Papadopoulos, Ph.D. | 214,815,636 | 11,003,480 | 179,336 | 23,953,528 | |||||||||||||||||||
George Poste, DVM, Ph.D., FRS | 222,946,800 | 2,868,484 | 183,168 | 23,953,528 | |||||||||||||||||||
Julie Anne Smith | 222,931,638 | 2,887,658 | 179,156 | 23,953,528 | |||||||||||||||||||
Jack L. Wyszomierski | 219,480,647 | 6,314,657 | 203,148 | 23,953,528 | |||||||||||||||||||
2.Ratification of Ernst & Young LLP as Exelixis’ independent registered public accounting firm: Exelixis stockholders ratified the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 2, 2026.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||
| 243,302,343 | 6,391,854 | 257,783 | — | |||||||||||||||||
3.Approval, on an advisory basis, of the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement (Say on Pay): Exelixis stockholders approved the Say on Pay proposal.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||
| 218,948,303 | 6,761,611 | 288,538 | 23,953,528 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC. | |||||||||||
| June 2, 2025 | /s/ Jeffrey J. Hessekiel | ||||||||||
| Date | Jeffrey J. Hessekiel | ||||||||||
| Executive Vice President and General Counsel | |||||||||||